ArticleClinical immunology (Orlando, Fla.)2013
Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.
Article in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Two subsets of regulatory CD8iScience · 2025Article
- CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders.Frontiers in immunology · 2025Article
- Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen.Frontiers in immunology · 2024Article
- The TNFα/TNFR2 axis mediates natural killer cell proliferation by promoting aerobic glycolysis.Cellular & molecular immunology · 2023Article
- Review
- Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.Frontiers in oncology · 2022Review
- Efficacy of low-dose hCG on FET cycle in patients with recurrent implantation failure.Frontiers in endocrinology · 2022Article
- FoxP3Frontiers in immunology · 2022Article
- TFNR2 in Ischemia-Reperfusion Injury, Rejection, and Tolerance in Transplantation.Frontiers in immunology · 2022Review
- Harnessing CD8Cells · 2021Review
- Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.Advances in experimental medicine and biology · 2021Article
- TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4Advances in experimental medicine and biology · 2021Article
- TNFR2: Role in Cancer Immunology and Immunotherapy.ImmunoTargets and therapy · 2021Review
- The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.Frontiers in cell and developmental biology · 2021Review
- Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.Frontiers in immunology · 2021Review
- Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4Frontiers in immunology · 2021Article
- Isatis root polysaccharide promotes maturation and secretory function of monocyte-derived dendritic cells.BMC complementary medicine and therapies · 2020Article
- Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.Frontiers in cell and developmental biology · 2020Review
- Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.Trends in immunology · 2019Review
- Gene expression profile of human T cells following a single stimulation of peripheral blood mononuclear cells with anti-CD3 antibodies.BMC genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We report that polyclonal CD8regs generated in one week ex-vivo with anti-CD3/28 beads and cytokines rapidly developed suppressive activity in vitro sustained by TGF-β. In immunodeficient mice, these CD8regs demonstrated a markedly protective, IL-10 dependent activity against a xeno-GVHD. They expressed IL-2Rα/β, Foxp3, TNFR2, and the negative co-stimulatory receptors CTLA-4, PD-1, PD-L1 and Tim-3. Suppressive activity in vitro correlated better with TNFR2 and PD-L1 than Foxp3. Blocking studies suggested that TNF enhanced PD-L1 expression and the suppressive activity of the CD8regs generated. Unlike other polyclonal CD4 and CD8 Tregs, these CD8regs preferentially targeted allogeneic T cells, but they lacked cytotoxic activity against them even after sensitization. Unlike CD4regs, these CD8regs could produce IL-2 and proliferate while inhibiting target cells. If these CD8regs can persist in foreign hosts without impairing immune surveillance, they could serve as a practical remission-inducing product for the treatment of autoimmune diseases, graft-versus-host disease, and allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.